title: Transforming regulatory science 2012: making a difference.
abstract: "What does not change is the will to change."-Charles Olson, "The Kingfishers"The world is in the midst of scientific revolutions that can transform medicine and public health. Yet translation to needed products remains slow and expensive. There are major opportunities for new regulatory science to help transform product development and evaluation. A plan by the US Food and Drug Administration (FDA), "Advancing Regulatory Science," identifies eight priorities and numerous actions to help catalyze transformation. Scientific excellence and collaboration, including public and private sectors, are essential for change that benefits health and economies globally.
authors.affiliation: Office of the Chief Scientist/Office of the Commissioner, US Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland, USA. jesse.goodman@fda.hhs.gov
authors.forename: J L
authors.initials: JL
authors.lastname: Goodman
mesh_terms: D003299:Cooperative Behavior; D004335:Drug and Narcotic Control / Q000191:economics / Q000379:methods / Q000639:trends*; D006301:Health Services Needs and Demand / Q000191:economics / Q000639:trends*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics / Q000592:standards*; D011634:Public Health / Q000191:economics / Q000639:trends*; D012106:Research / Q000191:economics / Q000639:trends; D012586:Science / Q000191:economics / Q000639:trends; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics
chemical_list: D004364:Pharmaceutical Preparations